These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

362 related items for PubMed ID: 16518894

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
    MMW Fortschr Med; 2003 Jun 26; 145(26):59. PubMed ID: 12916343
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Therapy of erectile dysfunction. Hard facts support sildenafil].
    MMW Fortschr Med; 2003 Sep 04; 145(35-36):50-1. PubMed ID: 14584211
    [No Abstract] [Full Text] [Related]

  • 5. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction].
    Chen Q, Wang N, Yao F, Lu X.
    Zhonghua Nan Ke Xue; 2004 Apr 04; 10(4):302-4. PubMed ID: 15148932
    [Abstract] [Full Text] [Related]

  • 6. PDE-5 inhibitors: current status and future trends.
    Masson P, Lambert SM, Brown M, Shabsigh R.
    Urol Clin North Am; 2005 Nov 04; 32(4):511-25, viii. PubMed ID: 16291042
    [Abstract] [Full Text] [Related]

  • 7. Oral drug treatment of erectile dysfunction.
    Int J Impot Res; 2003 Dec 04; 15 Suppl 7():S27-9. PubMed ID: 14695970
    [No Abstract] [Full Text] [Related]

  • 8. Re: Long-term efficacy of sildenafil and tachyphylaxis effect.
    Carson CC.
    J Urol; 2002 Jul 04; 168(1):205. PubMed ID: 12073960
    [No Abstract] [Full Text] [Related]

  • 9. Vasoactive pharmacotherapy to cure erectile dysfunction: fact or fiction?
    Burnett AL.
    Urology; 2005 Feb 04; 65(2):224-30. PubMed ID: 15708027
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
    MMW Fortschr Med; 2004 Apr 15; 146(16):62. PubMed ID: 15222506
    [No Abstract] [Full Text] [Related]

  • 15. Sildenafil in the treatment of erectile dysfunction.
    Budenholzer B.
    N Engl J Med; 1998 Sep 03; 339(10):701-2. PubMed ID: 9729142
    [No Abstract] [Full Text] [Related]

  • 16. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
    Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C.
    Int J Impot Res; 1996 Jun 03; 8(2):47-52. PubMed ID: 8858389
    [Abstract] [Full Text] [Related]

  • 17. In vivo and in vitro response of corpus cavernosum to phosphodiesterase-5 inhibition in the hypercholesterolaemic rabbit.
    Firoozi F, Longhurst PA, White MD.
    BJU Int; 2005 Jul 03; 96(1):164-8. PubMed ID: 15963142
    [Abstract] [Full Text] [Related]

  • 18. [Effectiveness duration determines selection].
    MMW Fortschr Med; 2006 Jul 20; 148(29-30):54-5. PubMed ID: 16910411
    [No Abstract] [Full Text] [Related]

  • 19. Commentary on apomorphine versus sildenafil for erectile dysfunction.
    Carson CC.
    J Urol; 2008 May 20; 179(5 Suppl):S95-6. PubMed ID: 18405768
    [No Abstract] [Full Text] [Related]

  • 20. [Erectile dysfunction: an update on new therapeutic options].
    Roumeguère T.
    Acta Urol Belg; 2000 May 20; 68(2):41-2. PubMed ID: 11098588
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.